Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia VP Friedman Is Among PhRMA Favorites For FDA Commissioner

Executive Summary

Pharmacia Senior VP Michael Friedman's recent letter to the New England Journal of Medicine regarding the use of Cytotec (misoprostol) in pregnant women should help continue his candidacy to return to FDA as commissioner.

You may also be interested in...



FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner

FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.

FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner

FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.

RU-486 Lower-Dose, Home-Administered Misoprostol Being Evaluated

The Population Council is planning a trial to demonstrate that a 200 mg dose of the abortifacient Mifeprex is effective and that the misoprostol component of the regimen can be safely used at home.

Related Content

UsernamePublicRestriction

Register

PS037308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel